{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Leung YY"],"funding":["Janet D. Cottrelle Foundation","Alberta Precision Laboratories","Cancer Research Society","VGH and UBC Hospital Foundation","Gynecologic Cancer Initiative at the University of British Columbia","Cure our Ovarian Cancer","BC Cancer Foundation","NCI NIH HHS","Management Office at APL NASA","Ovarian Cancer Canada"],"pagination":["e74"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12426737"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["36(5)"],"pubmed_abstract":["<h4>Objective</h4>With the development of novel antibody-drug conjugates (ADCs), folate receptor alpha (FOLR1) is a promising therapeutic target for the treatment of platinum-resistant tubo-ovarian carcinomas. The main aims of this study were to assess FOLR1 protein expression in a large cohort of ovarian carcinoma histotypes. To inform future clinical trial design we identified molecular correlates of FOLR1 expression in low-grade serous carcinoma (LGSC).<h4>Methods</h4>One thousand five hundred forty-seven ovarian carcinoma samples from 5 different Canadian cohorts were successfully evaluated by immunohistochemistry for FOLR1 expression using the PS2+ system. Statistical analyses with clinicopathological parameters, LGSC molecular subtypes, and overall survival (OS) were performed.<h4>Re"],"journal":["Journal of gynecologic oncology"],"pubmed_title":["FOLR1 as a therapeutic target in platinum-resistant ovarian carcinoma: unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma."],"pmcid":["PMC12426737"],"funding_grant_id":["RS21-609","P30 CA118100","RS21-608"],"pubmed_authors":["Hoenisch J","Tinker AV","Bittner M","Kobel M","Carey MS","Llaurado-Fernandez M","Kim H","Wong NKY","Schmid J","Cameron A","Da-Anoy A","Ghesquiere C","Cook LC","Gaillard S","Leung YY","Dhillion G","Dawson A"],"additional_accession":[]},"is_claimable":false,"name":"FOLR1 as a therapeutic target in platinum-resistant ovarian carcinoma: unique expression patterns across ovarian carcinoma histotypes and molecular subtypes of low-grade serous carcinoma.","description":"<h4>Objective</h4>With the development of novel antibody-drug conjugates (ADCs), folate receptor alpha (FOLR1) is a promising therapeutic target for the treatment of platinum-resistant tubo-ovarian carcinomas. The main aims of this study were to assess FOLR1 protein expression in a large cohort of ovarian carcinoma histotypes. To inform future clinical trial design we identified molecular correlates of FOLR1 expression in low-grade serous carcinoma (LGSC).<h4>Methods</h4>One thousand five hundred forty-seven ovarian carcinoma samples from 5 different Canadian cohorts were successfully evaluated by immunohistochemistry for FOLR1 expression using the PS2+ system. Statistical analyses with clinicopathological parameters, LGSC molecular subtypes, and overall survival (OS) were performed.<h4>Re","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Sep","modification":"2026-04-08T18:37:06.949Z","creation":"2026-04-08T10:01:49.784Z"},"accession":"S-EPMC12426737","cross_references":{"pubmed":["40150910"],"doi":["10.3802/jgo.2025.36.e74"]}}